VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DNTH
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DNTHDianthus Therapeutics, Inc.
$83.98$3.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. DNTH
  4. Financial Ratios

Dianthus Therapeutics, Inc. (DNTH) Financial Ratios

Latest Ratios: P/E Ratio -121.0x · EV/EBITDA N/A · ROE -38.4%. (2016–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

DNTH Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$3.5B$1.6B$726M$54M$24M$243M$344M$561M$190M——
Enterprise Value$3.5B$1.5B$705M$-78144401$9M$112M$286M$496M$132M——
P/E Ratio →-121.03——————————
P/S Ratio1289.98764.98116.4818.973.69164.92—————
P/B Ratio6.433.162.060.320.321.412.393.971.30——
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

DNTH EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—740.57113.06-27.651.4275.73—————
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

DNTH Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin100.0%100.0%100.0%100.0%100.0%100.0%—————
Operating Margin-8739.3%-8739.3%-1633.7%-1704.7%-462.9%-886.6%—————
Net Profit Margin-7973.3%-7973.3%-1362.8%-1541.2%-443.8%-888.1%—————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-38.4%-38.4%-32.6%-35.9%-23.1%-8.3%-52.6%-53.5%-58.7%-119.6%-104.3%
ROA-35.9%-35.9%-30.7%-33.2%-20.9%-7.5%-46.4%-48.2%-54.3%-107.9%-83.2%
ROIC-34.4%-34.4%-41.5%-75.1%-44.5%-15.5%-72.9%-76.2%-104.5%-1647.4%—
ROCE-41.6%-41.6%-38.8%-39.4%-23.4%-7.9%-52.9%-56.4%-60.8%-120.4%-102.5%

DNTH Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.000.000.000.000.01——————
Debt / EBITDA———————————
Net Debt / Equity—-0.10-0.06-0.78-0.20-0.76-0.40-0.46-0.40-1.02-0.50
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage——————-19.90———-56.86

Net cash position: cash ($51M) exceeds total debt ($1M)

DNTH Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio13.3213.3215.2218.429.9716.6313.2610.6213.9512.684.71
Quick Ratio13.3213.3215.2218.429.9716.6313.2610.6213.9512.684.71
Cash Ratio13.1613.1614.9218.049.1816.2913.0210.3213.6812.451.98
Asset Turnover—0.000.020.020.080.01—————
Inventory Turnover———————————
Days Sales Outstanding—18.2947.2461.74320.69——————

DNTH Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$38M$33M$5M$4M$3M$3M$2M$2M$2M$2M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Cash runway shortfall and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Multiples Distorted by Pre-Commercial Earnings

Based on reported figures, DNTH trades at a P/E of -123.98 and a P/S of 1321.47, multiples that are mathematically meaningless against near-zero earnings and a $2.04M TTM revenue base, making the price-to-book of 6.59 the more informative anchor.

The negative P/E and extreme P/S reflect a market price anchored to the clinical pipeline rather than to any earnings or sales stream, so these multiples should be treated as non-diagnostic. The P/B of 6.59 compared with peers such as IMVT at 6.53 and ALXO at 2.40 suggests DNTH is priced in line with or above similarly staged competitors on book value. Investors should monitor whether this premium is justified by DNTH103 probability-adjusted value rather than balance-sheet support, since book value here is largely a product of recent equity raises.

Minimal Debt Keeps Solvency Risk Low

According to recent SEC filings, DNTH carried roughly $1.2M of total debt at 2026Q3 against a D/E ratio near 0.00, a leverage profile that is effectively unlevered and sits well below peer ratios of 0.20 for ALXO and 0.18 for RCUS.

Interest coverage and D/EBITDA cannot be meaningfully computed because operating income is deeply negative, so traditional debt-service metrics provide no comfort or warning. The low absolute debt load means covenant and refinancing risk is limited, which shifts the solvency question entirely toward equity funding capacity. This may indicate that financing risk is a dilution question rather than a creditor question, and investors should monitor the next equity raise timing.

Liquidity Ratios Mask Thin Operating Runway

As reported in the balance sheet, DNTH's current ratio of 30.02 at 2026Q3 looks exceptionally strong, but cash of roughly $51M to $55.7M against quarterly operating outflows near $50M implies a runway potentially under one year.

A current ratio above 30 is driven by a large current asset pool that is dominated by cash and short-term investments relative to minimal current liabilities, not by any durable operating strength. Quick ratio equals current ratio here because inventory is absent, so the test of stress resilience depends solely on cash burn duration. Based on reported figures, if burn persists at present levels, a dilutive financing event may be required well before the liquidity ratio itself deteriorates, which warrants further investigation into management's runway disclosures.

Returns Oscillate Without Compounding Capital

Based on reported figures, DNTH's ROIC swung from -37.9% in 2024Q2 to -5.6% in 2026Q2 and ROE moved between -4.2% and 18.8%, a pattern driven by non-operating items rather than improving operational returns.

The 18.8% ROE in 2025Q4 coincides with a $97.9M net income against a -$69.5M operating loss, indicating the spike is a non-operating gain and not evidence of compounding. Underlying ROIC remains negative across the series, which suggests the company is consuming invested capital rather than earning returns on it. Investors should treat the reported ROE trend with caution and focus on whether operating losses narrow as trial spending matures.

Working Capital Metrics Lack Operational Meaning

As reported in financial statements, DNTH's DSO fluctuated from 62 days in 2024Q2 to 826 days in 2025Q4 on a revenue base that is largely legacy and non-recurring, rendering the cash conversion cycle uninformative.

DSO spikes reflect lumpy collaboration or milestone receivables rather than a steady customer credit cycle, so the efficiency signal is driven by revenue timing rather than collection performance. Inventory, DIO, and the cash conversion cycle are effectively unavailable because the company has no manufactured product, and DPO readings are sparse and volatile. This suggests working capital analysis offers limited insight, and attention should shift to cash burn per quarter instead.

Gross Margin Misleads on Pre-Commercial Economics

Based on reported figures, DNTH's 100% gross margin appears to reflect milestone revenue with no cost of goods sold rather than durable unit economics, while operating margin fell to -244.9% in 2025Q4, obscuring the true cost base.

A 100% gross margin is an accounting artifact of revenue recognized without COGS and should not be used to infer pricing power or commercial scalability. The more relevant metric is the operating loss relative to cash on hand, or quarterly cash burn divided by runway, which better captures the financing need. Modeling should rely on probability-adjusted pipeline value rather than margin-based earnings power, and investors should monitor whether operating expenses scale further with Phase 2 enrollment.

Download Financial Ratios Data

Includes 30+ ratios · 10 years · Updated daily

Consensus & Technical Research Suite
Open DNTH Terminal

DNTH Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

DNTH — Frequently Asked Questions

Quick answers to the most common questions about buying DNTH stock.

What is Dianthus Therapeutics, Inc.'s P/E ratio?

Dianthus Therapeutics, Inc.'s current P/E ratio is -121.0x. This places it at the 50th percentile of its historical range.

What is Dianthus Therapeutics, Inc.'s ROE?

Dianthus Therapeutics, Inc.'s return on equity (ROE) is -38.4%. The historical average is -52.7%.

Is DNTH stock overvalued?

Based on historical data, Dianthus Therapeutics, Inc. is trading at a P/E of -121.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Dianthus Therapeutics, Inc.'s profit margins?

Dianthus Therapeutics, Inc. has 100.0% gross margin and -8739.3% operating margin.